Author correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy.
Wei, Andrew H Panayiotidis, Panayiotis Montesinos, Pau Laribi, Kamel Ivanov, Vladimir Kim, Inho Novak, Jan Stevens, Don A Fiedler, Walter Pagoni, Maria
Wei, Andrew H
Panayiotidis, Panayiotis
Montesinos, Pau
Laribi, Kamel
Ivanov, Vladimir
Kim, Inho
Novak, Jan
Stevens, Don A
Fiedler, Walter
Pagoni, Maria
Abstract
No abstract available
MIDER Authors
Citations
Altmetric:
Date
2021-10-26
Type
Corrigendum
Subject
Haematology
Collections
Citation
Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Stevens DA, Fiedler W, Pagoni M, Bergeron J, Ting SB, Hou JZ, Anagnostopoulos A, McDonald A, Murthy V, Yamauchi T, Wang J, Chyla B, Sun Y, Jiang Q, Mendes W, Hayslip J, DiNardo CD. Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy. Blood Cancer J. 2021 Oct 26;11(10):171. doi: 10.1038/s41408-021-00565-6. Erratum for: Blood Cancer J. 2021 Oct 1;11(10):163
Journal / Source Title
Blood Cancer Journal
DOI
10.1038/s41408-021-00565-6
PMID
34702803
Publisher
Nature Publishing Group
Publisher’s URL
http://www.nature.com/bcj/index.html